-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Central point | Mutations in 7 genes can independently predict the overall survival of AML patients in different cytogenetic groups who are ≥60 years of age and receive intensive treatment
Central point | Mutations in 7 genes can independently predict the overall survival of AML patients in different cytogenetic groups who are ≥60 years of age and receive intensive treatment
stem cell
In order to design a simple and reproducible classifier to predict the overall survival (OS) of AML patients ≥60 years of age receiving 7+3 regimen treatment, Itzykson and other researchers analyzed 471 patients (median 68 years) from the ALFA1200 trial Of 37 genes were sequenced
The overall survival and recurrence-free survival of patients in the ALFA1200 cohort grouped by cytogenetic risk
The overall survival and recurrence-free survival of patients in the ALFA1200 cohort grouped by cytogenetic riskThe 84 patients with poor cytogenetic risk and the other 387 patients with good cytogenetic risk (n=13), moderate (n=339), or untested (n=35) had significant differences in mutation patterns and OS
TP53 and KRAS gene mutations are independently associated with shorter OS in patients with poor cytogenetic risk.
The overall survival and recurrence-free survival of patients in the ALFA1200 cohort grouped according to the ALFA decision-making tool
The overall survival and recurrence-free survival of patients in the ALFA1200 cohort grouped according to the ALFA decision-making toolCombining the cytogenetic risk and mutations of these 7 genes, 39.
Combining the cytogenetic risk and mutations of these 7 genes, 39.
Overall survival of patients grouped by ALFA decision tool in 3 validation cohorts
Overall survival of patients grouped by ALFA decision tool in 3 validation cohortsIn 3 independent verification cohorts, 31.
In 3 independent verification cohorts, 31.
The ALFA decision-making tool is a simple, stable and discriminative prognostic model that is suitable for predicting the overall survival of AML patients over 60 years of age receiving intensive chemotherapy
Original source:
Raphael Itzykson, et al.
Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy
in this message
